SCHEMBL15092126

SCHEMBL15092126

CC1(C)OB(c2ccc(NS(=O)(=O)c3cccc(F)c3)c(F)c2)OC1(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.45
KIT P10721 1/20 0.45
CA1 P00915 3/20 0.44
CA2 P00918 3/20 0.44
CA9 Q16790 3/20 0.44
BRD4 O60885 1/20 0.43
MOGAT2 Q3SYC2 2/20 0.41
CA12 O43570 1/20 0.40
CA3 P07451 1/20 0.40
CA4 P22748 1/20 0.40
CA6 P23280 1/20 0.40
CA5A P35218 1/20 0.40
CA7 P43166 1/20 0.40
CA14 Q9ULX7 1/20 0.40
CA5B Q9Y2D0 1/20 0.40
KMT2A Q03164 1/20 0.40
LMNA P02545 1/20 0.40
SLC10A2 Q12908 1/20 0.40
SLC10A1 Q14973 1/20 0.40
SLC10A6 Q3KNW5 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15092124 0.89 PKM (0.47) KITCA1CA2CA9KMT2A
SCHEMBL15091833 0.87 CA1 (0.49) KITCA1CA2CA9MOGAT2
SCHEMBL15091859 0.87 KEAP1 (0.54) AXLCA1CA2CA9PGR
SCHEMBL15092051 0.86 CA1 (0.51) CA1CA2CA9MOGAT2CA12
SCHEMBL28820629 0.83 CA1 (0.48) CA1CA2CA9CA12CA3
SCHEMBL30720423 0.82 AXL (0.44) AXLCA1CA2CA9BRD4
SCHEMBL15091823 0.82 CA1 (0.47) KITCA1CA2CA9CA12
SCHEMBL31438924 0.81 SLC22A12 (0.44) KITCA1CA2CA9CA12
SCHEMBL29675527 0.81 SLC22A12 (0.44) KITCA1CA2CA9CA12
SCHEMBL15092120 0.81 SLC22A12 (0.44) KITCA1CA2CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130178472-A1 ARYLSULFONAMIDE PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION OF SAME, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178472-A1 ARYLSULFONAMIDE PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION OF SAME, AND THERAPEUTIC USE THEREOF NDUFS2, NDUFS6, NDUFS3 AXL 668/4885KIT 304/4885CA1 4666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.